Towards Healthcare
U.S. Viral Vector and Plasmid DNA Manufacturing Market to Rise at 15.72% CAGR ...

U.S. Viral Vector and Plasmid DNA Manufacturing Market Expansion Forecast

Market insights predict, the U.S. viral vector and plasmid DNA manufacturing industry is expected to grow from USD 2.85 billion in 2024 to USD 12.31 billion by 2034, driven by a CAGR of 15.72%. The boom in cell and gene therapies, advancements in personalized medicine, and high R&D investments support the expansion of industrial manufacturing in the U.S. The rise of gene editing technologies, the rapid increase in clinical trials, and diverse therapeutic applications have led to the growth of the cell and gene therapy sector in the U.S.

Content

  • Insight Code: 6237
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The U.S. viral vector and plasmid DNA manufacturing market in 2025 is valued at USD 3.3 billion and is projected to climb to USD 12.31 billion by 2034, with a CAGR of 15.72% over the forecast period.

The U.S. viral vector and plasmid DNA manufacturing market includes five segments such as product type, workflow, application, end user, and scale of manufacturing.

Key trends include increasing adoption of suspension cell culture systems, growing integration of automation, closed-system bioprocessing, and high-yield and scalable production platforms

FDA, CIRM, CSU, CDC, National Institutes of Health.
Any Questions